The influence of H2-receptor antagonist drugs on the plasma lipid pattern has been studied prospectively in 51 patients treated with cimetidine (26 patients) or ranitidine (25 patients) for gastroenterological diseases. Total and HDL cholesterol and total triglycerides have been measured. Ranitidine did not influence the investigated parameters, while cimetidine produced a significant increase in the HDL cholesterol serum concentration (P = 0.008).
Introduction
Plasma high density lipoprotein (HDL) concen- trations are important in the evaluation of atherosclerotic risk (Gordon et al., 1977; Miller & Miller, 1975) . Cimetidine-induced increase of HDL-cholesterol has been recently reported in normolipidaemic subjects (Bolton et al., 1983) and in one patient with familial type 1110 hyperlipoproteinemia (Miller & Lewis, 1983) .
These findings and the different effects of cimetidine and ranitidine on hepatic drug metabolism (Henry etal., 1980; Puurunen & Pelkonen, 1979; Somogyi & Gugler, 1982) and on androgen activity (Funder et al., 1979; Pearce et al., 1980; Winters et al., 1979 ) stimulated us to investigate the action of these two drugs on plasma lipid patterns in patients suffering from gastroenterological disease.
Methods
Fifty-six patients (44 males and 12 females; mean age 54 years) entered the study and were randomly allocated to cimetidine (400 mg twice daily) or ranitidine (150 mg twice daily) treatment for 5 weeks. Endoscopic diagnoses were duodenal ulcers (38), gastric ulcers (11) and reflux oesophagitis (7).
Uncooperative patients and subjects treated with cimetidine, ranitidine or hypolipidaemic drugs in the previous 2 weeks did not participate.
Before entering the study, patients underwent a full physical examination and parameters reported in Table 1 
Results
Twenty-six patients treated with cimetidine and 25 treated with ranitidine completed the study. Three patients on cimetidine and two on ranitidine withdrew for non-medical reasons. Both groups were comparable but the average age of the ranitidine group was slightly greater than that of the cimetidine group (P = 0.04) ( Table 1) .
Neither cimetidine nor ranitidine modified the total cholesterol (before 174.0 33.3, after 181.4 + 30.4 mg/100 ml, and before 170.7 + 41.5 after 175.2 + 34.0 mg/100 ml respectively) or triglycerides (before 138.9 + 77.0 after 145.9 + 62.6 mg/100 ml, and before 120.8 + 32.7 after 137.4 + 49.1 mg/100 ml respectively) concentration. Ranitidine did not affect the HDLcholesterol level (before 39.7 + 11.7, after 38.0 + 13.9 mg/100 ml) while cimetidine increased it significantly (from 36.9 9.3 to 41.9 12.34 mg/100 ml) (Student's t-test for paired data within the group: P = 0.008) (Figure 1 ).
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Our study has demonstrated a significant increase in HDL-cholesterol concentration in patients treated with cimetidine for dyspepsia and studied without reference to the basal lipid profile. Bolton et al. (1983) noted a decrease of antipyrine clearance and, simultaneously, an increase of HDL-cholesterol concentration during cimetidine treatment in normolipidaemic subjects. Miller & Ldwis (1983) suggested that these results could be due to the anti-androgenic action of cimetidine (Funder & Mercer, 1979; Winters et al., 1979) .
Our results showing different effects of cimetidine and ranitidine on HDL-cholesterol could be associated with differential androgenic effects. 
